Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease With Anti TNF-α Therapy

Samsung Medical Center20 enrolled

Overview

This study investigated the expression of T-cell immunoglobulin- and mucin-domain-containing molecule 3 (TIM-3) in the colonic mucosa and/or the peripheral blood of children with Crohn's disease during anti TNF-α (infliximab) therapy.

The immunoregulatory effects of TIM-3 on patients with Crohn's disease according to the treatment have not yet been investigated.

Study Type

INTERVENTIONAL

Allocation

Purpose

BASIC_SCIENCE

Masking

NONE

Enrollment

Conditions

Crohn's Disease

Interventions

InfliximabDRUG

Eligibility

Sex: ALLMin age: 13 YearsMax age: 17 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * •Pediatric patients who were diagnosed with severe Crohn's disease who require infliximab treatment * confirmed diagnostic of Crohn's disease in clinical, endoscopic and histological findings Exclusion Criteria: * •patients who has proven to have infliximab antibody

Locations (1)

Samsung Medical Center

Seoul, South Korea

Outcomes

Primary Outcomes

Expression of TIM-3 and Correlation With Disease Activity in Pediatric Crohn's Disease with anti TNF-α Therapy

Disease Activity Index (PCDAI) scores, Peripheral blood for TIM-3 mRNA expression

Time frame: 1-year treatment period

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.